advertisement
Abstract #5792 Published in IGR 2-1
Glaucoma medical therapy: A comparison of timolol and latanoprost
Bonsanto DAnnali di Ottalmologia e Clinica Oculistica 1999; 125:89-94
Latanoprost is a PGF2α analogue able to reduce intraocular pressure (IOP) in glaucomatous eyes. The authors valued many multicentric randomized, double-blind placebo studies in which latanoprost 0.005% was administered once a day, while timolol 0.5% was administered twice a day. Both these drugs effectively reduced IOP, but latanoprost 0.005% administered at 8 P.M. seemed to be more effective than timolol 0.5%. At an ocular level, latanoprost caused a slight increase in conjunctival hyperemia which was well tolerated, and an iris-increased pigmentation in mixed color irises without clinical diseases. Consequently, latanoprost can be considered a useful drug in glaucoma therapy as is timolol, but with no contraindications and better patient compliance. LA: Italian
Dr. D. Bonsanto, Clinica Oculistica II, Policlinico S. Orsola, Bologna; Italy
Classification:
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
